Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GnRH agonist + recombinant human chorionic gonadotropin
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
GnRH agonist + recombinant human chorionic gonadotropin is a combination regimen used in assisted reproductive technology (ART) for final oocyte maturation (dual trigger) during in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles. The regimen co-administers a gonadotropin-releasing hormone (GnRH) agonist (such as triptorelin, leuprolide, or buserelin) and recombinant human chorionic gonadotropin (rhCG, such as choriogonadotropin alfa) to trigger ovulation. The GnRH agonist induces an endogenous surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), mimicking the natural mid-cycle surge, while the rhCG provides sustained LH-like activity. This dual trigger approach is designed to improve oocyte yield, maturation rates, and embryo quality, particularly in patients undergoing controlled ovarian hyperstimulation, while potentially reducing the risk of ovarian hyperstimulation syndrome (OHSS) compared to high-dose hCG alone.
- Other names
- GnRH agonist + rhCGGnRHa + rhCGdual triggerdual trigger regimen
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on GnRH agonist + recombinant human chorionic gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GnRH agonist + recombinant human chorionic gonadotropin.